FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S.FDA expressed openness to an alternative ...
Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the ...
Happening soon: The Scleroderma Awareness Open: Pickleball with a Purpose on the Wauwatosa Patch calendar ...
Atomic force microscopy (BioAFM) drives innovation in cosmetics and healthcare, ensuring product efficacy through precise ...
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a ...
Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...
Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory ...
The Philadelphia hospital treats complex cases and expands access to transplant care for patients who may not qualify ...
InvestorsHub on MSN
Quoin advances QRX003 development after positive FDA meeting on Netherton syndrome
Quoin Pharmaceuticals (NASDAQ:QNRX) said it received encouraging regulatory feedback from the U.S. Food and Drug ...
Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products The agreement will allow ...
Profiles of private companies featured at the Healthcare Investors Meeting on 31 March 2026 at the Genolier innovation hub.
As we close 2025 and enter what we expect to be a defining year for Allogene Therapeutics, Inc., the environment around us is shifting. Cell therapy has entered a phase defined by evidence, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results